21-amino

Endothelin-2 (49-69), human (Human endothelin-2) 是一种由 21 个氨基酸组成的血管活性肽。它可与 G 蛋白连接的跨膜受体，ET-RA 和ET-RB 结合。

BMS 310705 (21-Aminoepothilone B) 是 Epothilone B 的类似物，靶向卵巢癌、肾癌、膀胱癌和肺癌等恶性肿瘤。BMS 310705 通过线粒体介导的途径诱导显着的细胞凋亡 (apoptosis)。

4-AMino-1,3,5-triMethylpyrazole是一个片段分子，CAS号为28466-21-9，可作为分子拼接、扩展和修饰的重要骨架，为新型候选药物的设计与筛选提供结构基础与研究工具，常用于药物发现、药物合成等相关研究。

7-Amino-4-(trifluoromethyl)coumarin (Coumarin 151) 是一种荧光标记物，其激发和发射波长分别为400和500 nm，可用来灵敏的检测蛋白酶。

gamma-preprotachykinin amide (72-92) acetate 是一种 21 个氨基酸的肽，属于速激肽 (TK) 家族，在其 C 末端序列中包括神经激肽 A (NKA)。它对中枢 NK-2 受体的亲和力高于 NKA；它对 NK-1 受体的亲和力较低，但是，它有效地刺激唾液分泌，这是由 NK-1 受体激活介导的。

N-Arachidonoyl taurine is an arachidonoyl amino acid. It is oxygenated by 12(S)- and 15(S)-lipoxygenase and is converted to 12-HETE-taurine (12-HETE-T) in murine resident peritoneal macrophages. N-Arachidonoyl taurine is an activator of the transient receptor potential vanilloid (TRPV) channels TRPV1 and TRPV4 (EC50s = 28 and 21 μM, respectively). It increases calcium flux in HIT-T15 pancreatic β-cells and INS-1 rat islet cells when used at a concentration of 10 μM and increases insulin secretion from 832 13 INS-1 pancreatic β-cells. The levels of N-arachidonoyl taurine are changed in mouse brain following administration of δ9-tetrahydrocannabinol (δ9-THC).

Histone H3 (21-44)-GK-biotin is a peptide fragment of histone H3 that corresponds to amino acid residues 22-45 of the human histone H3.1 and 3.2 sequences and is biotinylated via a C-terminal GK linker. Histone H3 (21-44) contains a lysine residue at position 23 that is subject to acetylation, an arginine at position 26 subject to methylation, and a serine at position 28 subject to phosphorylation, as well as lysine residues at positions 27 and 36 that are subject to methylation and acetylation. Histone H3 (21-44)-GK-biotin has been used as a substrate for the primate-specific histone methyltransferase PR domain-containing protein 7 (PRDM7) to determine substrate specificity.

High affinity JNK inhibitor (Ki values are 25-50 nM). Inhibits JNK via competitive binding of the ATP-binding site of active, phosphorylated JNK. Exhibits > 40-fold selectivity for JNK over p38, ERK, IKK2, protein kinase C, Lck and ZAP70. Hepatoprotective. Also inhibits HCMV replication. Uehara et al (2004) c-Jun N-terminal kinase mediates hepatic injury after rat liver transplantation. Transplantation. 78 324 PMID:15316358 |Uehara et al (2005) JNK mediates hepatic ischemia reperfusion injury. J.Hepatol. 42 850 PMID:15885356 |Ma et al (2007) A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. J.Am.Soc.Nephrol. 18 472 PMID:17202416 |Ma et al (2009) Blockade of the c-Jun amino terminal kinase prevents crescent formation and halts established anti-GBM glomerulonephritis in the rat. Lab.Invest. 89 470 PMID:19188913 |Zhang et al (2015) The c-Jun N-terminal kinase inhibitor SP600125 inhibits human cytomegalovirus replication. J.Med.Virol. 87 2135 PMID:26058558 |Vasilevskaya et al (2015) Inhibition of JNK sensitizes hypoxic colon cancer cells to DNA-damaging agents. Clin.Cancer.Res. 21 4143 PMID:26023085

TAS-103 is a dual inhibitor of DNA topoisomerase I II, used for cancer research. TAS-103 is a dual inhibitor of DNA topoisomerase I II. TAS-103 (0.1-10 μM) is active on CCRF-CEM cells, with an IC50 value of 5 nM. TAS-103 (0.1 μM) significantly increases levels of topo IIα FITC immunofluorescence in individual CCRF-CEM cells[1]. TAS-103 (0.01-1 μM) is highly cytotoxic to Lewis lung carcinoma (LLC) cells, and Liposomal TAS-103 is almost as active as free TAS-103[2]. TAS-103 inhibits the viability of HeLa cells, with an IC50 of 40 nM. TAS-103 (10 μM) disrupts signal recognition particle (SRP) complex formation, and induces destabilization of SRP14 and SRP19 and its eventual degradation[3]. TAS-103 (30 mg kg, i.v.) causes significant tumor growth suppression in mice bearing Lewis lung carcinoma (LLC) cells, without obvious body weight loss, and the liposomal TAS-103 is more active than free TAS-103[2]. [1]. Padget K, et al. An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells. Biochem Pharmacol. 2000 Sep 15;60(6):817-21. [2]. Shimizu K, et al. Cancer chemotherapy by liposomal 6-[12-(dimethylamino)ethyl]aminol-3-hydroxy-7H-indeno[2,1-clquinolin-7-one dihydrochloride (TAS-103), a novel anti-cancer agent. Biol Pharm Bull. 2002 Oct;25(10):1385-7. [3]. Yoshida M, et al. A new mechanism of 6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)quinolin-7-one dihydrochloride (TAS-103) action discovered by target screening with drug-immobilized affinity beads. Mol Pharmacol. 2008 Mar;73(3):987-94. Epub 2007 Dec 18.

Histone H3 (21-44)-GK-biotin is a peptide fragment of histone H3 that corresponds to amino acid residues 22-45 of the human histone H3.3 sequence and is biotinylated via a C-terminal GK linker. Unlike histone H3.1 and H3.2, the histone H3.3 variant contains a serine residue at position 31 that is phosphorylated during late prometaphase and metaphase of mitosis. Histone H3 (21-44) also contains lysine residues at positions 23, 27, and 36 that are subject to methylation and acetylation, all of which have a role in the regulation of gene expression, and a serine residue at position 28 that is subject to phosphorylation during mitosis.

TLQP-21 TFA, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor1 (C3aR1) agonist (EC50: mouse TLQP-21=10.3 μM; human TLQP-21=68.8μM). TLQP-21 TFA activates C3aR1 to induce an increase of intracellular Ca2+. TLQP-21 TFA is used for the research in regulation of nociception and other relevant physiologic functions[1][2]. TLQP-21 TFA is a peptide of 21 amino acids. At a dose of 3 μM TLQP-21 induces up to ~69% of the corresponding contraction promoted by acetylcholine[1][2]. [1]. Elena Bresciani , et al. TLQP-21, A VGF-Derived Peptide Endowed of Endocrine and Extraendocrine Properties: Focus on In Vitro Calcium Signaling. Int J Mol Sci. 2019 Dec 24;21(1):130. [2]. Cheryl Cero, et al. The TLQP-21 Peptide Activates the G-protein-coupled Receptor C3aR1 via a Folding-Upon-Binding Mechanism. ructure. 2014 Dec 2;22(12):1744-1753.

Histone H3 (21-44), derived from a sequence of 21-44 amino acids of histone H3, is commonly employed as a substrate, particularly for protein arginine methyltransferase assays, where methylation activity is being examined.

Histone H3 (1-21) is a truncated form of the Histone H3 protein consisting of amino acids 1 to 21. It serves as a common substrate for methyltransferase assays targeting Histone 3 at lysine 4 and lysine 9, as well as for acetyltransferase assays targeting Histone 3 at lysine 9 and lysine 14.

2-Amino-4-(ethylthio)butanoic acid 是一种有用的有机化合物，可用于生命科学领域的相关研究。其产品编号为 T66823，CAS号为 67-21-0。

Forigerimod (IPP-201101) 是一种 CD4T 细胞调节剂。Forigerimod 是 U1 小核核糖核蛋白 70 kDa 的 21 个氨基酸片段，在 Ser140 位点被磷酸化。Forigerimod 可以有效抑制自噬。Forigerimod 可用于系统性红斑狼疮 (SLE) 等自身免疫性疾病的研究。

Forigerimod TFA (IPP-201101 TFA) 为 CD4T 细胞调节剂，属于 U1 小核核糖核蛋白 70 kDa 的 21 个氨基酸片段，并在 Ser140 位点磷酸化。它能有效抑制自噬，适用于系统性红斑狼疮 (SLE) 等自身免疫性疾病的研究。

Catestatin TFA，一个含有21个氨基酸残基、阳离子性疏水性肽，作为内源性肽，调节心脏功能及血压。它通过烟碱型乙酰胆碱受体(nAChRs)以非竞争性方式抑制儿茶酚胺释放，功能为烟碱类拮抗剂。

LL-37 GKE acetate是具有21个氨基酸的多肽和LL-37的活性结构域，抑制lps诱导的血管一氧化氮产生，对人培养平滑肌细胞溶血和凋亡的毒性小于LL-37，具有抗菌活性和治疗败血症的潜力。

Mad1 (6-21) TFA，作为Mad1蛋白的6-21片段，与哺乳动物Sin3A PAH2结合，其Kd约为29 nM。

ELAAWCRWGFLLALLPPGIAG TFA (P5) 是由大鼠HER2 neu蛋白衍生的21个氨基酸长的肽段（氨基酸序号5至25）。该化合物在携带HER2阳性肿瘤的小鼠模型中，能够诱发细胞毒性T淋巴细胞(CTL)的反应。

ELAAWCRWGFLLALLPPGIAG (P5) 是源自大鼠HER2 neu蛋白的21个氨基酸长肽（氨基酸5-25）。此肽可诱导携带HER2阳性肿瘤小鼠中的细胞毒性T淋巴细胞（CTL）反应。

BNP (1-21), Pro (Human) 是一种由21个氨基酸组成的心脏激素多肽。作为B型利钠肽(BNP)的一部分，与心房利钠肽高度同源，共同构成了心脏的双利钠肽系统。BNP 主要参与心脏发生的调节，并涉及向子宫外环境过渡的生理进程。

Acetyl-Heme-Binding Protein 1 (1-21) (human)为一种由Acetyl-Heme-Binding Protein 1前21个氨基酸组成的短肽。该肽具有与血红素结合的能力，参与血红素代谢及血红蛋白释放过程。

Spike binding peptide 1 (SBP1) 为对应于血管紧张素转换酶2 (ACE2) 的第21至43位氨基酸的肽。已将脂质纳米粒子 (LNPs) 包裹的抗病毒化合物奥司他韦磷酸盐与SBP1结合并通过体外研究评估其控制释放奥司他韦磷酸盐的长期潜力。SBP1 (2%) 固定于交联的羟基丙烯酸酯和乙基黄原酸乙酯网络，提高了对严重急性呼吸系统冠状病毒2(SARS-CoV-2)刺突糖蛋白，亦称表面糖蛋白，的网络捕获效率。